Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report

MET tyrosine kinase inhibitors, capmatinib and tepotinib, have been recently introduced for the treatment of advanced NSCLC with MET exon 14 skipping mutations. Although interstitial lung disease (ILD) induced by these drugs is reported, its optimal management and whether they can be rechallenged re...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashiguchi, Mizuha Haraguchi, Sato, Takashi, Yamamoto, Hiroki, Watanabe, Rinako, Kagyo, Junko, Domoto, Hideharu, Shiomi, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888201/
https://www.ncbi.nlm.nih.gov/pubmed/35252894
http://dx.doi.org/10.1016/j.jtocrr.2021.100271
_version_ 1784661085926719488
author Hashiguchi, Mizuha Haraguchi
Sato, Takashi
Yamamoto, Hiroki
Watanabe, Rinako
Kagyo, Junko
Domoto, Hideharu
Shiomi, Tetsuya
author_facet Hashiguchi, Mizuha Haraguchi
Sato, Takashi
Yamamoto, Hiroki
Watanabe, Rinako
Kagyo, Junko
Domoto, Hideharu
Shiomi, Tetsuya
author_sort Hashiguchi, Mizuha Haraguchi
collection PubMed
description MET tyrosine kinase inhibitors, capmatinib and tepotinib, have been recently introduced for the treatment of advanced NSCLC with MET exon 14 skipping mutations. Although interstitial lung disease (ILD) induced by these drugs is reported, its optimal management and whether they can be rechallenged remain unclear. We report the first successful case of tepotinib treatment after capmatinib-induced ILD. Switching MET tyrosine kinase inhibitors after drug-induced ILD could be a clinical option, which warrants further investigation.
format Online
Article
Text
id pubmed-8888201
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88882012022-03-03 Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report Hashiguchi, Mizuha Haraguchi Sato, Takashi Yamamoto, Hiroki Watanabe, Rinako Kagyo, Junko Domoto, Hideharu Shiomi, Tetsuya JTO Clin Res Rep Case Report MET tyrosine kinase inhibitors, capmatinib and tepotinib, have been recently introduced for the treatment of advanced NSCLC with MET exon 14 skipping mutations. Although interstitial lung disease (ILD) induced by these drugs is reported, its optimal management and whether they can be rechallenged remain unclear. We report the first successful case of tepotinib treatment after capmatinib-induced ILD. Switching MET tyrosine kinase inhibitors after drug-induced ILD could be a clinical option, which warrants further investigation. Elsevier 2021-12-28 /pmc/articles/PMC8888201/ /pubmed/35252894 http://dx.doi.org/10.1016/j.jtocrr.2021.100271 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Hashiguchi, Mizuha Haraguchi
Sato, Takashi
Yamamoto, Hiroki
Watanabe, Rinako
Kagyo, Junko
Domoto, Hideharu
Shiomi, Tetsuya
Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report
title Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report
title_full Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report
title_fullStr Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report
title_full_unstemmed Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report
title_short Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report
title_sort successful tepotinib challenge after capmatinib-induced interstitial lung disease in a patient with lung adenocarcinoma harboring met exon 14 skipping mutation: case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888201/
https://www.ncbi.nlm.nih.gov/pubmed/35252894
http://dx.doi.org/10.1016/j.jtocrr.2021.100271
work_keys_str_mv AT hashiguchimizuhaharaguchi successfultepotinibchallengeaftercapmatinibinducedinterstitiallungdiseaseinapatientwithlungadenocarcinomaharboringmetexon14skippingmutationcasereport
AT satotakashi successfultepotinibchallengeaftercapmatinibinducedinterstitiallungdiseaseinapatientwithlungadenocarcinomaharboringmetexon14skippingmutationcasereport
AT yamamotohiroki successfultepotinibchallengeaftercapmatinibinducedinterstitiallungdiseaseinapatientwithlungadenocarcinomaharboringmetexon14skippingmutationcasereport
AT watanaberinako successfultepotinibchallengeaftercapmatinibinducedinterstitiallungdiseaseinapatientwithlungadenocarcinomaharboringmetexon14skippingmutationcasereport
AT kagyojunko successfultepotinibchallengeaftercapmatinibinducedinterstitiallungdiseaseinapatientwithlungadenocarcinomaharboringmetexon14skippingmutationcasereport
AT domotohideharu successfultepotinibchallengeaftercapmatinibinducedinterstitiallungdiseaseinapatientwithlungadenocarcinomaharboringmetexon14skippingmutationcasereport
AT shiomitetsuya successfultepotinibchallengeaftercapmatinibinducedinterstitiallungdiseaseinapatientwithlungadenocarcinomaharboringmetexon14skippingmutationcasereport

Ejemplares similares